Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.

Targeted oncology - 1 Jan 2024

Maiorano Brigida Anna, De Giorgi Ugo, Verzoni Elena, Maiello Evaristo, Procopio Giuseppe, Conteduca Vincenza, Di Maio Massimo

Abstract excerpt

BACKGROUND: PARP inhibitors (PARPis) are effective treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) as single agents or in combination with androgen receptor-targeted agents (ARTA). However, a clinically relevant adverse effect of these agents is hematological toxicity, a typical class adverse event (AE), which can lead to treatment modifications and discontinuations....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neutropenia

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prostatic Neoplasms, Castration-Resistant

Share to Thrombocytopenia

Source

Open in PubMed Open full text

Identifiers

PMID: 37993604
DOI: 10.1007/s11523-023-01016-x
PMCID: PMC10830661

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.PMID 37993604Read ↗

PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence.Semantic proximity Read ↗

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.Semantic proximity Read ↗

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging TrendsSemantic proximity Read ↗

The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.Semantic proximity Read ↗

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate CancersSemantic proximity Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United StatesSemantic proximity Read ↗

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient SelectionSemantic proximity Read ↗

Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.Semantic proximity Read ↗

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Cancer: Systematic Review and Network Meta-AnalysisSemantic proximity Read ↗

PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCASemantic proximity Read ↗

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.